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Abstract Biased integration remains a key challenge for gene therapy based on lentiviral vector
technologies. Engineering of next-generation lentiviral vectors targeting safe genomic harbors for
insertion is therefore of high relevance. In a previous paper (Cai et al., 2014a), we showed the use
of integrase-defective lentiviral vectors (IDLVs) as carriers of complete gene repair kits consisting of
zinc-finger nuclease (ZFN) proteins and repair sequences, allowing gene correction by homologous
recombination (HR). Here, we follow this strategy to engineer ZFN-loaded IDLVs that insert
transgenes by a homology-driven mechanism into safe loci. This insertion mechanism is driven by
time-restricted exposure of treated cells to ZFNs. We show targeted gene integration in human
stem cells, including CD34+ hematopoietic progenitors and induced pluripotent stem cells (iPSCs).
Notably, targeted insertions are identified in 89% of transduced iPSCs. Our findings demonstrate
the applicability of nuclease-loaded ‘all-in-one’ IDLVs for site-directed gene insertion in stem cell-
based gene therapies.
DOI: 10.7554/eLife.12213.001
Introduction
Uncontrolled genomic insertion of transgenes, leading to insertional mutagenesis, remains a primary
challenge for safe genetic therapies. Lentiviral vectors offer an effective gene delivery route, but also
suffer from prevalent gene insertion into transcriptionally active regions (Schro¨der et al., 2002;
Modlich et al., 2009). Novel strategies to attain targeted gene integration (TGI) into predetermined
genomic loci are highly warranted. TGI using lentiviral vectors can be achieved by delivering donor
sequences for insertion by homologous recombination (HR) into double-strand breaks (DSBs) gener-
ated by tailored endonucleases (Lombardo et al., 2011). Development of programmable nucleases,
ZFNs, TALENs, and now CRISPR/Cas9, has made effective gene disruption feasible, even in stem
cells, but genetic operations involving TGI in stem cells are still challenged by low membrane perme-
ability, low HR efficiency, and high sensitivity to external manipulation (Genovese et al.,
2014; Hockemeyer et al., 2011; Hendel et al., 2015; Tay et al., 2013; Tiyaboonchai et al., 2014).
We previously established genomic editing in cells treated with ‘all-in-one’ lentiviral particles
loaded with locus-targeted ZFN proteins and a donor sequence flanked by homology arms
(Cai et al., 2014a). Here, building on these findings, we report a simple method for establishing TGI
by treating cells with integrase-defective lentiviral vectors (IDLVs) packaged with both the trans-
gene-containing donor template and ZFN proteins fused to the N-terminus of lentiviral Gag and
GagPol polypeptides. Locus-directed cleavage and TGI is evident in cell lines, CD34+ hematopoietic
stem cells, and induced pluripotent stem cells (iPSCs) upon transduction with ZFN-loaded vectors.
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Notably, the prevalence of TGI in two safe harbors in the human genome, the CCR5 and AAVS1
loci, is high in iPSCs treated with ZFN-loaded lentiviral vectors, resulting in non-mosaic clones har-
boring a site-directed gene insertion and no additional cutting at top-ranked off-target sites.
Results
IDLVs harboring both ZFN protein and vector RNA with the transgene flanked by homology arms
are here designated ‘IDLV-ZFN(locus)/gene’, where ‘gene’ refers to the transgene cassette flanked
by homology arms and transferred by the vector. Principles of production, transduction, and integra-
tion of such vectors are illustrated in Figure 1A. Together with a dimer of lentiviral vector RNAs,
approximately 5000 copies of Gag and GagPol polypeptides (of which about half carry a ZFN fused
to the matrix protein) form the capsid, which is wrapped in a segment of the membrane during bud-
ding from the producer cells. ZFNs are released from Gag and GagPol upon cleavage by the viral
protease during maturation of the virus particle. The mature virus particles contain two types of
ZFNs, left and right, which upon DNA binding in the target cell form a catalytically active dimer.
After viral entry in the target cells and endosomal escape, vector RNA is reverse transcribed to
DNA, which can serve as donor for homology-directed insertion at targeted breakage sites gener-
ated by the co-delivered ZFNs (Figure 1A, lower panel).
To visualize the enrichment of ZFN-containing lentiviral polypeptides at the membrane of the pro-
ducer cells, we transfected HEK293T cells with GagPol plasmid harboring either the coding
sequence for a HA-tagged ZFN (HA-ZFN(gfp)) recognizing the egfp gene or the egfp gene itself
fused to the 5’-end of gag gene and analyzed the virus-producing cells using confocal microscopy
(Figure 1B and Figure 1—figure supplement 1A). By staining with an antibody specific for the tag,
we found that the ZFNs were highly enriched at the cell membrane (Figure 1B). We then visualized
the lentiviral particles (designated LPs since the vector was not included) and found for both LP-HA-
ZFN(gfp) and LP-eGFP co-localization of the fusion protein with viral p24 protein (Figure 1C and Fig-
ure 1—figure supplement 1B and C), suggesting that ZFN (or eGFP) proteins were indeed pack-
aged into the LPs. To measure the lifespan of LP-delivered ZFNs in transduced cells, HEK293 cells
were synchronized at 4˚C for 60 min before fixation at different time points (1, 12, 24, and 48 hr,
respectively) after transduction with ZFN-loaded LPs. Already within the first hour after exposure to
LP-HA-ZFN(gfp), the ZFNs were easily detectable inside the cells, whereas after 24 hr essentially all
ZFNs had been degraded or diluted (Figure 1D). These findings showed that nucleases delivered by
LPs were immediately available after transduction and that the time of action was restricted due to
decay of the proteins.
We then performed proof-of-efficacy studies by transducing HEK293T cells with IDLVs (500 ng
p24), with or without AAVS1-directed ZFNs, carrying an eGFP expression cassette (IDLV-ZFN
(AAVS1)/egfp). Initially, three days post-transduction, a higher frequency of eGFP+ cells was
observed among cells transduced with IDLV/egfp than for cells transduced with IDLV-ZFN(AAVS1)/
egfp (59.1% versus 44.7%), indicating that the overall transduction potential was higher for IDLVs
that did not carry ZFNs (Figure 1E and Figure 1—figure supplement 1D and 1E). Nevertheless, at
later time points 2.5% of the cells were eGFP+ after treatment with IDLV-ZFN(AAVS1)/egfp, whereas
the percentage dropped to below 1% in IDLV/egfp-treated cells (Figure 1E and Figure 1—figure
supplement 1E). PCR amplification and sequencing of the 5’ and 3’ junction sites including part of
the donor sequence and the regions flanking the inserted transgene cassette showed that events of
correct integration into AAVS1 locus were evident after treatment with IDLV-ZFN(AAVS1)/egfp,
whereas PCR products indicative of site-directed insertion did not appear for IDLV/egfp (Figure 1F).
However, DSBs were not repaired by HR only, and mismatches introduced by non-homologous end
joining (NHEJ) were detected in 5% of the AAVS1 alleles, as measured by Surveyor nuclease assay
(Figure 1G). To evaluate the levels of TGI with another reporter gene, we treated HEK293T cells
with IDLV-ZFN(AAVS1)/fluc carrying AAVS1-targeted ZFNs and a firefly luciferase (fluc) expression
cassette. Indeed, fluc gene expression was maintained for up to 18 days after transduction with
IDLV-ZFN(AAVS1)/fluc (Figure 1H), although the levels dropped from the initial 3-day time point,
where episomal forms were still likely to support expression. For IDLV/fluc, in contrast, luminescence
dropped to almost undetectable levels. TGI of the fluc gene into the AAVS1 locus was verified by
PCR (Figure 1I), and the rate of NHEJ estimated to be 8% (Figure 1J).
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Figure 1. Proof-of-efficacy studies and characterization of ZFN-loaded IDLVs carrying a transgene flanked by homology arms facilitating insertion by
homologous recombination. (A) Schematic illustration of the production, transduction and integration of IDLVs carrying ZFNs and transgene.
Figure 1 continued on next page
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Next, we created ZFN-loaded IDLVs carrying the puromycin resistance gene (IDLV-ZFN(AAVS1)/
puro) allowing us to easily isolate single puromycin-resistant clones and further scrutinize AAVS1-tar-
geted integration events by Southern blot analysis (Figure 1K). Among 16 clones generated with
IDLV-ZFN(AAVS1)/puro, a 2.2-kb fragment, indicative of precise TGI by HR, was detected in 11
clones (Figure 1L). Other types of integrations, resulting in lower-mobility bands, were evident in
the five remaining clones. Notably, two clones (clone 5 and clone 13) showed a 3.7-kb band, and
these clones therefore were among clones that were analyzed by Southern blotting using another
restriction enzyme and an AAVS1-specific probe (Figure 1—figure supplement 1F and 1G). A com-
mon 6.4-kb band was observed for clones 5 and 13 (Figure 1—figure supplement 1G), suggesting
that the full-length lentiviral DNA in these two cases was captured and inserted by chance into the
ZFN-induced DSB at the AAVS1 locus. These findings demonstrated that site-directed gene insertion
into ZFN-generated DSBs also occurred, although less frequently, in an HR-independent fashion.
We analyzed 15 additional puromycin-resistant clones by PCR and found that 13 out of these
clones yielded PCR products indicative of TGI (Figure 1—figure supplement 1H). In total, 84% (26/
31) of the analyzed clones contained a targeted insertion of the puro gene in the AAVS1 locus. In
contrast, the fragments detected by Southern blot analysis of IDLV/puro-treated clones had variable
sizes (Figure 1M), indicating that the integrations were random events that occurred at different
genomic locations.
To demonstrate the feasibility of this approach in stem cells, we isolated CD34+ hematopoietic
stem cells from human cord blood and focused initially on optimizing lentiviral transduction rates for
optimal ZFN delivery. We first verified that ZFN-loaded VSV-G-pseudotyped LPs loaded with
AAVS1-directed ZFNs resulted in targeted cleavage upon transduction of CD34+ cells. Hence, indels
introduced through repair by NHEJ were found in 5% of the alleles (Figure 2—figure supplement
1A). Next, we compared the capacity of recombinant human fibronectin (RetroNectin) and EF–C
peptides, the latter recently discovered artificial peptide nanofibrils, to support virus entry to CD34+
cells (Yolamanova et al., 2013; Lump et al., 2015). In our setting, the presence of EF-C allowed
transduction of 85.1% of the cells with a standard eGFP-encoding lentiviral vector, whereas between
27.5 and 30.8% of the cells were transduced in the presence of RetroNectin (Figure 2—figure sup-
plement 1B). Therefore, we chose to include EF-C for targeted integration in CD34+ cells.
In the first of two protocols (Figure 2A, orange labeling), we transduced CD34+ cells derived
from two different donors with IDLV-ZFN(AAVS1)/egfp or IDLV/egfp (MOI = 5) and analyzed for
eGFP+ cells 9 days post-transduction (Figure 2B). On average, treatment with IDLV-ZFN(AAVS1)/
egfp resulted in (0.49 ± 0.14)% eGFP+ cells, which was significantly higher than the percentage of
Figure 1 continued
Enrichment of ZFN-fused viral polypeptides and donor-carried viral RNAs at the cell membrane leads to assembly of ZFN-containing virions. During
virus maturation, the polypeptides are cleaved into enzymatic and structural proteins by HIV protease. In the transduced cells, the viral RNAs are
reverse transcribed to DNA that serves as donor for repair of ZFN-induced DSB by HR, leading to site-specific insertion of a gene expression cassette
(here containing the puro gene). RT, reverse transcription; HR, homologous recombination. (B–D) Immunostaining and confocal microscopy of producer
cells, virions, and transduced cells. Green, HA-tagged ZFN-GagPol or ZFN; blue, nuclei; red, p24; scale bar indicates 5 mm. (B) HEK293T cells co-
transfected by pMD.2G, pHA-ZFNL(gfp)-PH-gagpol-D64V and pHA-ZFNR(gfp)-PH-gagpol-D64V. (C) Incorporation of ZFNs into lentiviral particles was
confirmed by co-localization of HA-ZFNs and p24 (see also Figure 1—figure supplement 1B). (D) Recording of the ZFN lifespan in HEK293 cells
treated with LP-HA-ZFN(gfp) by immunostaining at different time points after treatment. (E–G) TGI by IDLV-ZFN(AAVS1)/egfp in HEK293T cells. (E)
IDLV-ZFN(AAVS1)/egfp transduction resulted in higher percentage of eGFP+ cells relative to the IDLV/egfp counterpart after 10 and 18 days. (F) PCR
analyses of TGI at the AAVS1 locus. Illustration shows primer designs with one primer matching inside the insert and one in the flanking region allowing
amplification of 5’ and 3’ junction sites (5’ and 3’ JS). Amplification of the CCR5 locus included as a control. (G) Rate of imprecise gene repair by NHEJ
in target cells. (H-J) TGI by IDLV-ZFN(AAVS1)/fluc in HEK293T cells. (H) Higher levels of Fluc expression in IDLV-ZFN(AAVS1)/fluc-treated HEK293T cells
relative to IDLV/fluc-treated cells 10 and 18 days after transduction. (I) PCR analyses of TGI at the AAVS1 locus by IDLV-ZFN(AAVS1)/fluc. (J) Rates of
imprecise NHEJ in target cells induced by IDLV-ZFN(AAVS1)/fluc. (K) Schematic representation of Southern blot for analysis of TGI at AAVS1 locus
using IDLV-ZFN(AAVS1)/puro. The probe used is indicated by the dark blue line; cleavage site for the used restriction enzyme (BstXI) is also indicated.
(L–M) Southern blot analyses of puromycin-resistant HEK293T clones resulting from treatment with IDLV-ZFN(AAVS1)/puro (L) and IDLV/puro (M).
Fragments indicated with * are results of NHEJ leading to imprecise transgene insertion in the AAVS1 locus.
DOI: 10.7554/eLife.12213.002
The following figure supplement is available for figure 1:
Figure supplement 1. Characterization of protein delivery by ZFN-loaded IDLVs.
DOI: 10.7554/eLife.12213.003
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eGFP+ cells (0.07 ± 0.03)% measured after transduction with the IDLV/egfp control without ZFNs
(Figure 2B). PCR analyses confirmed events of TGI by IDLV-ZFN(AAVS1)/egfp, but not by IDLV/egfp
(Figure 2C). Notably, IDLV-ZFN(AAVS1)/egfp transduction only slightly affected the cell viability
(Figure 2D), and cell proliferation was not disturbed by the virus treatment (Figure 2E). Encouraged
by this, we reasoned that the efficiency could be further increased (i) by using higher MOIs, (ii) by
pretreating CD34+ cells with Vpx-loaded lentiviral particles (to degrade the reverse transcription
inhibitor SAMHD1 [Laguette et al., 2011]), and (iii) by treating the cells with an extra dose of ZFNs
delivered by LP-ZFNs. Indeed, using this improved protocol 2 (Figure 2A, green labeling), we were
able to increase the percentage of eGFP+ cells to (0.98 ± 0.13)% after transduction with IDLV-ZFN
(AAVS1)/egfp (Figure 2F). Also based on this protocol, TGI in the bulk was confirmed by PCR analy-
sis (Figure 2G). Notably, IDLV-ZFN(AAVS1)/egfp treatment did not compromise the colony-forming
capacity of CD34+ cells (Figure 2H). In accordance with the flow cytometry data, three eGFP+
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Figure 2. Targeted gene integration mediated by IDLV-ZFN(AAVS1)/egfp in CD34+ cells. (A) Schematic illustration of protocols used for IDLV-ZFN
(AAVS1)/egfp transduction in CD34+ cells. (B) Flow cytometry analysis showing the percentage of eGFP+ cells after transduction using protocol 1
(Figure 2A, orange labeling). Experiments were performed in triplicates using CD34+ cells from two different donors (donor 1 and donor 2 marked by
black and red color, respectively). Representative dot plot is shown on the top right. (C) PCR analyses of targeted gene integration. The primer sets
used were same as in Figure 1F. (D) Cell death was measured 4 days after transduction. IDLV-ZFN(AAVS1)/egfp treatment was performed in triplicates.
(E) Growth curve of transduced cells and non-transduced cells. (F) Flow cytometry analysis showing the percentage of eGFP+ cells after transduction
using protocol 2 (Figure 2A, green labeling). Experiments were performed in triplicates using CD34+ cells from donor 3. Representative dot plot is
shown on the top right. (G) PCR analyses of targeted gene integration. The primer sets used were the same as in Figure 1F. (H) The number of
colonies formed from IDLV-ZFN(AAVS1)/egfp-transduced and non-transduced CD34+ cells. The experiments were performed in triplicates, and the
numbers of eGFP+ colonies are provided above each bar.
DOI: 10.7554/eLife.12213.004
The following figure supplement is available for figure 2:
Figure supplement 1. Allelic disruption and gene insertion after lentiviral ZFN delivery in human CD34+ cells.
DOI: 10.7554/eLife.12213.005
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colonies (example shown in Figure 2—figure supplement 1C) were identified out of a total of 302
analyzed colonies.
Ways of engineering cells by TGI may be of particular interest for therapeutic modification and
use of iPSCs. To establish TGI in iPSCs using lentiviral protein transduction, we first evaluated the
permissiveness of iPSCs to LPs loaded with ZFNs targeting the AAVS1 and CCR5 loci, respectively.
LP-ZFN(AAVS1) and LP-ZFN(CCR5) disrupted 4% and 8%, respectively, of the targeted alleles in
iPSCs (Figure 3A).
We then transduced iPSCs with IDLV-ZFN(AAVS1)/puro. Of the approximately 500 puromycin-
resistant clones formed from 50,000 transduced iPSCs (Figure 3B), we initially randomly picked, iso-
lated and expanded eight clones (clones 1–8) for further analysis. From a subsequent experiment we
picked 15 additional clones (clones 9–23). PCR amplification of the 5’ and 3’ junction sites showed
that TGI had occurred in 19 out of the 23 clones (Figure 3C and D). Findings based on Southern
blot analysis of clones 9–23 were consistent with the PCR analysis and confirmed that 11 of these 15
clones contained an AAVS1-directed insertion (Figure 3D). Eight out of the 11 clones harbored a
precise, homology-directed transgene insertion, whereas only one of the two junction sites in the
remaining 3 clones (clones 9, 17, and 18) was intact. Hence, the 5’ junction site was intact in clone
17, whereas clones 9 and 18 contained an intact 3’ junction site, indicating that site-directed inser-
tion in these cases involved both HR and NHEJ. Sequence analysis of the 5’ and 3’ junction sites
amplified from clones 1–8 showed junctions sequences indicative of precise, homology-driven inser-
tion (Figure 3E and Supplementary file 1A). For one particular clone, clone 7, we were not able to
amplify the 469-bp AAVS1 fragment, suggesting that both alleles in this clone contained a TGI
(Figure 3C). Interestingly, sequencing of the AAVS1 locus provided evidence of biallelic cleavage in
at least one of the clones (clone 5), resulting in a 1-bp insertion in the allele that did not contain the
transgene (Supplementary file 1A). Stemness of TGI-modified iPSCs was verified by characterization
of a single representative clone using alkaline phosphatase (AP) and the TRA-1-60 pluripotency
marker (Figure 3F). Also, genomic integrity was confirmed by karyotyping (Figure 3G).
To detect potential off-target cleavage by the virus-delivered ZFNs, we first sequenced the three
top-ranked off-target sites in clones 1–8, but did not identify indels in any of these loci
(Supplementary file 1B). We then isolated genomic DNA from a pool of more than 100 puromycin-
resistant iPSC clones and confirmed by PCR analysis the presence of TGI events in the pool
(Figure 3H, insert). Then, next-generation sequencing was performed on PCR amplicons represent-
ing the on-target AAVS1 locus as well as seven top-ranked off-target sites. Among this pool of
clones, most of which carry an AAVS1-directed gene insertion, we were not able to detect indels at
off-target positions, whereas 3% of the AAVS1 alleles that were not already targeted by transgene
insertion contained indels (Figure 3H and Figure 3—figure supplement 1A). Altogether, our find-
ings demonstrated high levels of ZFN specificity and precise TGI in the AAVS1 locus in iPSCs treated
with IDLV-ZFN(AAVS1)/puro vectors, resulting in at least one TGI event in 19 of 23 analyzed iPSC
clones.
To demonstrate that such features of the ‘all-in-one’ gene delivery system was not limited to
insertion into the AAVS1 locus, we produced IDLVs (designated IDLV-ZFN(CCR5)/puro) carrying
ZFNs targeting the human CCR5 locus as well as vector RNA carrying the PGK-puro cassette flanked
by homology arms matching the CCR5 locus. Transduction of iPSCs with IDLV-ZFN(CCR5)/puro
resulted in effective colony formation (Figure 3I). Among the puromycin-resistant clones, we ran-
domly picked, isolated and expanded 15 clones (clones 1–15) and showed by PCR analysis of each
of these colonies that the transgene cassette in all 15 clones (100%) had been inserted site-specifi-
cally into the CCR5 locus (Figure 3J). For a single representative clone, stemness was verified using
alkaline phosphatase (AP) and the TRA-1-60 pluripotency marker (Figure 3K). Once again, we
pooled more than 100 puromycin-resistant iPSC clones and performed next-generation sequencing
on PCR amplicons amplified from the on-target locus and nine high-ranked off-target sites in the
pooled DNA sample (Figure 3L and Figure 3—figure supplement 1B). Notably, we identified an
indel in approximately 19% of the CCR5 alleles that did not already carry a TGI, demonstrating that
the second CCR5 allele was cleaved by ZFNs in approximately one of every five clones harboring a
CCR5-directed insertion. Importantly, off-target cleavage and indel formation by NHEJ was not evi-
dent in any of the nine analyzed off-target candidate loci. Hence, not even the CCR2 locus (off-tar-
get 3), which is highly homologous to the CCR5 site and a known off-target cleavage site for CCR5-
targeted ZFNs, harbored detectable levels of indels.
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Figure 3. Targeted gene integration in iPSCs by IDLV-ZFN(AAVS1)/puro and IDLV-ZFN(CCR5)/puro. (A) Gene disruption mediated by transduction of
LP-ZFN(AAVS1) and LP-ZFN(CCR5) in iPSCs. (B) Puromycin-resistant iPSC clones appearing after transduction with IDLV-ZFN(AAVS1)/puro. Clones were
stained with methylene blue. (C) PCR analyses of targeted gene integration by IDLV-ZFN(AAVS1)/puro in clones 1–8. Primer sets used for amplification
of 5’ and 3’ junction sites were the same as in Figure 1F, except that amplification of the AAVS1 locus without the insertion was included as a control.
(D) Southern blot (top) and PCR analyses (bottom) of targeted gene integration in clones 9–23 resulting from transduction with IDLV-ZFN(AAVS1)/puro.
Schematic illustration of Southern blot mimics that in Figure 1K, except that a longer puro probe was used. Fragments indicated with * are indicative
Figure 3 continued on next page
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In conclusion, lentivirus-based co-delivery of nuclease proteins and a HR donor represents a pow-
erful and safe approach for inserting transgenes into predetermined ‘safe harbors’ in the human
genome.
Discussion
On average, four out of five lentiviral integrations land in genes (Mitchell et al., 2004). It is still
unclear to which extent this biased integration pattern induces toxicity due to insertional mutagene-
sis, but new approaches to alter the integration properties of lentiviral vectors remain attractive. Dif-
ferent strategies have been employed to reprogram the integration machinery of lentiviral vectors
including (i) addition of a DNA-binding zinc-finger protein to the integrase (Bushman and Miller,
1997), (ii) fusion of a chromosomal binding domain to LEDGF, a cellular co-factor of the integrase
(Gijsbers et al., 2010), and (iii) insertion of lentiviral DNA intermediates by transposases and recom-
binases (Vink et al., 2009; Staunstrup et al., 2009; Moldt et al., 2011; Cai et al., 2014b). These
approaches successfully alter the integration preference, but do not allow site-specific insertion into
a preferred locus. Here, we present an alternative homology-directed insertion strategy facilitated
by nuclease-directed DNA cleavage. By co-packaging designer nucleases and donor sequences into
lentiviral vectors and utilizing cellular HR repair pathways to integrate the transgene, we can guide
lentiviral cargo toward a safe harbor in up to 84% of HEK293T cells and 89% of iPSCs that were
transduced with the ‘all-in-one’ vector system. The efficiency may likely be further improved by
exploiting heterodimer-forming rather than homodimer-forming FokI domains (Doyon et al., 2011).
TGI into the AAVS1 and CCR5 loci of stem cells has previously been achieved using HR-based
strategies exploiting two- or three-component systems based on delivery of plasmids, IDLVs, and
baculovirus vectors as well as combinations of mRNA encoding ZFNs and IDLVs serving as the HR
donor (Lombardo et al., 2011; Genovese et al., 2014; Tay et al., 2013; Tiyaboonchai et al.,
2014; Hockemeyer et al., 2009; Lei et al., 2011). Despite the potential of genetic therapies based
on TGI in stem cells, like CD34+ cells and iPSCs, existing technologies remain insufficient and highly
toxic (Genovese et al., 2014; Hoban et al., 2015; Merling et al., 2015). Exploiting the capacity of
lentiviruses to co-deliver nucleases and a transgene cassette, we showed TGI in CD34+ cells trans-
duced with ZFN-loaded IDLVs without affecting the viability, proliferation, or colony-forming capac-
ity of the cells. However, the efficiency was only modest, suggesting that a selective growth
advantage of the TGI-engineered cells, as in SCID-X1, would be required for successful engraftment.
Possibly, efficacy could be boosted by combining virus treatment with exposure to chemicals
enhancing stem cell self-renewal, by supplying NHEJ inhibitors (Chu et al., 2015), or by manipulat-
ing cell cycle conditions in favor of HR (Marniemi et al., 1975).
Stable transduction rates with ZFN-loaded IDLVs leading to TGI are undoubtedly reduced relative
to conventional lentiviral gene delivery strategies. In iPSCs, however, transduction with IDLVs carry-
ing ZFNs targeting either the AAVS1 or the CCR5 locus generated a high number of puromycin-
resistant clones. Remarkably, 34 out of a total of 38 analyzed clones contained the transgene
Figure 3 continued
of imprecise TGI involving NHEJ at either the 5’ or 3’ junction site. (E) Representative sequence chromatograms of amplified 5’ and 3’ junctions (see
also Supplementary file 1A). (F) Alkaline phosphatase (left) and TRA-1-60 (right) staining of a representative iPSC clone derived from IDLV-ZFN
(AAVS1)/puro treatment. (G) Karyotyping analysis of a representative iPSC clone generated after transduction with IDLV-ZFN(AAVS1)/puro. (H) Indel
frequencies obtained by deep sequencing of on- and top-ranked off-target sites in pools of iPSC clones generated by transduction with IDLV-ZFN
(AAVS1)/puro. Inserted PCR analysis confirms the presence of TGI in a pool of iPSCs consisting of approximately 110 iPSC clones. (I) Puromycin-
resistant iPSC clones appearing after transduction with IDLV-ZFN(CCR5)/puro. Clones were stained with methylene blue. (J) PCR analyses of targeted
gene integration in iPSCs (clones 1–15) obtained by transduction with IDLV-ZFN(CCR5)/puro. (J) Alkaline phosphatase (left) and TRA-1-60 (right) staining
of a representative iPSC clone derived from IDLV-ZFN(CCR5)/puro treatment. (L) Indel frequencies obtained by deep sequencing of on- and top-ranked
off-target sites in pools of iPSC clones generated by transduction with IDLV-ZFN(CCR5)/puro. Inserted PCR analysis confirms the presence of TGI in a
pool of iPSCs consisting of approximately 105 iPSC clones.
DOI: 10.7554/eLife.12213.006
The following figure supplement is available for figure 3:
Figure supplement 1. Deep sequencing analysis of cleavage frequencies at the on-target and top ranking off-target loci of AAVS1 (A) and CCR5 (B) in
pools of iPSC clones.
DOI: 10.7554/eLife.12213.007
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expression cassette inserted precisely into the locus targeted by the ZFNs. Also, as typically
observed in relation to the standard use of IDLVs, we found that a few clones contained an addi-
tional, randomly inserted transgene cassette, which could be of relevance for potential future thera-
peutic use. Importantly, however, we found that lentiviral ZFN protein delivery did not lead to
detectable off-target cleavage. Hence, cleavage in a total of 16 predicted off-target loci (7 for
AAVS1 and 9 for CCR5) did not appear as analyzed by deep sequencing of large pools of clones car-
rying the transgene cassette. If desired, this approach can be combined with removal of the selec-
tion marker by seamless excision, exploiting for example lentiviral protein transduction of piggyBac
transposase (Cai et al., 2014b). Remarkably, in a large pool of iPSCs, most if not all carrying a site-
targeted gene insertion in the CCR5 locus, off-target cleavage and indel formation at the neighbor-
ing CCR2 locus was not evident after deep sequencing analysis. This is in contrast to higher levels of
CCR2 targeting reported in previous studies using other delivery strategies based on adenoviral vec-
tors, plasmid transfection, or administration of recombinant proteins (Perez et al., 2008; Gaj et al.,
2012), suggesting that lentiviral delivery of site-targeted endonucleases supports safer engineering
of the genome. Together, our findings demonstrate that lentivirus particles can ferry programmable
nucleases, facilitating homology-driven, site-directed genomic insertion of a co-delivered transgene.
Such co-delivery ensures time-limited exposure of the treated cell to nucleases and, yet, results in
frequent TGI with particular applicability in iPSCs.
Materials and methods
Plasmid construction
To construct pLV/AAVS1-donor-fluc-PGK and pLV/AAVS1-donor-egfp-PGK, inserts were amplified
from pLV/fluc-PGK-PBT (Cai et al., 2014b) and pLV/egfp-PGK-PBT (cloned similarly as pLV/fluc-
PGK-PBT), respectively, using primer sets YJ219F-YJ210R (primers are listed in Supplementary file
2A). The inserts were subsequently digested by BsiWI/SalI and cloned into pLV/AAVS1-donor-LS
(Cai et al., 2014a) that was digested with the same pair of enzymes. pLV/AAVS1-donor-puro-PGK
and pLV/CCR5-donor-puro-PGK were cloned similarly by amplifying inserts from pLV/puro-PGK-PBT
using primer set YJ262F-YJ210R and ligated with pLV/AAVS1-donor-LS and pLV/CCR5-donor-LS
(Cai et al., 2014b), respectively. Restriction enzymes used for inserts and vectors were BsrGI/SalI
and BsiWI/SalI, respectively. All donor sequences are provided in Supplementary file 3. The packag-
ing construct, pMDlg/pRRE-D64V-218, for production of IDLVs was constructed by introducing a
D64V mutation into the integrase of pMDlg/pRRE by overlap PCR. For the first round PCR, primers
AgeI-int(s)-int-D64V(as) and int-D64V(s)-AccIII-int(as) were used, respectively, with pMDlg/pRRE as
the templates. For the second round PCR, primers AgeI-int(s) and AccIII-int(as) were used with the
PCR product from the first round as template. The inserts and vector pMDlg/pRRE were then both
digested by AgeI and AccIII before ligation.
Cells and culture conditions
HEK293 and HEK293T were cultured in Dulbecco’s Modified Eagle’s Medium (Lonza, Basel, Switzer-
land). Culture medium was supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/
ml streptomycin and 250 mg/ml L-glutamine. Human cord blood was obtained from Aarhus Univer-
sity Hospital. CD34+ cells were purified from umbilical cord blood using EasySep Human Cord Blood
CD34 Positive Selection Kit (STEMCELL Technologies, Grenoble, France) and cultured in StemSpan
serum-free expansion medium (STEMCELL Technologies) supplemented with human early-acting
cytokines (PeproTech, Rocky Hill, NJ) including stem cell factor (SCF) 100 ng/ml, Flt3 ligand (Flt3-L)
100 ng/ml, thrombopoietin (TPO) 50 ng/ml, and interleukin 3 (IL-3) 20 ng/ml and enhancer of self-
renewal UM171 50 nM (STEMCELL Technologies). Induced pluripotent stem cells, described in a
previous publication (Kang et al., 2015), were cultured using TeSR-E8 medium (STEMCELL Technol-
ogies) on Vitronectin XF (STEMCELL Technologies) coated culture dish. All cells were cultured at
37˚C and 5% (vol/vol) CO2.
Lentiviral vector production and titration
In this work, ‘LP’ (as in LP-ZFN(AAVS1) and ‘LP-ZFN(CCR5)) was used to designate lentiviral particles
which did not carry a vector genome but contained a pair of ZFN proteins targeting the AAVS1 and
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CCR5 locus, respectively. When a lentiviral genome was included, the vectors were referred to as
‘IDLVs’. IDLV-ZFN(AAVS1)/egfp, IDLV-ZFN(AAVS1)/puro and IDLV-ZFN(AAVS1)/fluc all contained a
pair of AAVS1-targeting ZFNs as well as RNAs, which upon reverse transcription formed DNA
donors for homologous recombination at the AAVS1 locus. The ‘donor’ genes carried by these vec-
tors were egfp, puro and firefly luciferase, respectively, all driven by the PGK promoter. Preparations
of LPs and IDLVs were produced as previously described (Cai et al., 2014a). Briefly, LP-ZFN(AAVS1)
and LP-ZFN(CCR5) were produced by co-transfection of pMD.2G, pZFNL(AAVS1 or CCR5)-PH-gag-
pol-D64V and pZFNR(AAVS1 or CCR5)-PH-gagpol-D64V. IDLV/egfp, IDLV/puro and IDLV/fluc were
produced by co-transfection pMD.2G, pRSV-Rev, pMDlg/pRRE-D64V-218, and donor-containing
vector (either pLV/AAVS1-donor-egfp-PGK, pLV/AAVS1-donor-puro-PGK or pLV/AAVS1-donor-fluc-
PGK). IDLV-ZFN(AAVS1)/egfp, IDLV-ZFN(AAVS1)/puro, IDLV-ZFN(AAVS1)/fluc and IDLV-ZFN(CCR5)/
puro were produced by co-transfection pMD.2G, pRSV-Rev, pMDlg/pRRE-D64V-218, pZFNL
(AAVS1)-PH-gagpol-D64V (or pZFNL(CCR5)-PH-gagpol-D64V), pZFNR(AAVS1)-PH-gagpol-D64V (or
pZFNR(CCR5)-PH-gagpol-D64V), and donor-containing vector (either pLV/AAVS1-donor-egfp-PGK,
pLV/AAVS1-donor-puro-PGK, pLV/AAVS1-donor-fluc-PGK, or pLV/CCR5-donor-puro-PGK). Concen-
trations of HIV-1 p24 were measured by ELISA assay (XpressBio, Frederick, MD) according to the
manufacturer’s protocol. The MOIs of IDLV-ZFN(AAVS1)/egfp and IDLV/egfp were determined by
virus transduction to HEK293T cells followed by flow cytometry analysis allowing quantification of
the percentage of eGFP+ cells three days after transduction.
Confocal microscopy
For confocal microscopy, HEK293T cells or HEK293 cells were seeded at a concentration of 2105
cells/well 1 day before transfection or transduction. HEK293T cells were co-transfected with 0.75 mg
pMD.2G and 1.3 mg pHA-ZFNL(gfp)-PH-gagpol-D64V (Cai et al., 2014a) and 1.3 mg pHA-ZFNR
(gfp)-PH-gagpol-D64V (Cai et al., 2014a) or with 0.75 mg pMD.2G and 2.6 mg pGFP-PH-gagpol-
D64V (Cai et al., 2014a). Cells were fixed after 24 hr. HEK293 cells were transduced with LP-HA-
ZFN(gfp) and incubated at 4˚C for 1 hr to synchronize virus entry. The cells were then incubated at
37˚C for 1 hr, 12 hr, 24 hr and 48 hr, respectively. To detect lentiviral particles, LP-HA-ZFN(gfp) and
LP-eGFP were attached to poly-L-lysine coated coverslips by spinoculation at 1200 g for 99 min. In
all the experiments, cells or lentiviral particles were washed three times with PBS before fixation with
4% paraformaldehyde. Coverslips were stored in 70% ethanol for at least 15 min. To visualize HA-
tagged ZFNs, fixed cells or lentiviral particles were incubated with mouse-derived primary HA mono-
clonal antibody (Covance, Princeton, NJ) and secondary Alexa Fluor 488 Donkey anti-Mouse IgG
(LifeTechnologies). To visualize p24, the lentiviral particles were stained with rabbit-derived primary
p24 polyclonal antibody (ThermoFisher Scientific, Waltman, MA) and secondary Alexa Fluor 568
Donkey-anti-Rabbit IgG (LifeTechnologies). The nuclei were stained by DAPI. Sequential imaging
was done by using a 488 nm line of a multiline argon laser (detection of Alexa-488), the 405 nm
diode laser (detection of DAPI) and 561 nm DPSS laser (detection of Alexa-568) on a confocal micro-
scope (LSM 710, ZEISS) using 63  oil immersion objective with a numerical aperture of 1.4.
Lentiviral vector transduction in CD34+ cells and iPSCs
In protocol 1, CD34+ cells were transduced with IDLV-ZFN(AAVS1)/egfp or IDLV/egfp at MOI = 5. In
protocol 2, CD34+ cells were pretreated with 300 ng p24 Vpx-loaded lentiviral particles for 6 hr and
then transduced with IDLV-ZFN(AAVS1)/egfp at MOI = 20. On the next day, cells were transduced
with 300 ng p24 LP-ZFN(AAVS1). Both protocols used EF-C nanofibrils to boost virus transduction to
CD34+ cells. The iPSCs were pretreated with 2 mM ROCK inhibitor (Sigma-Aldrich, St. Louis, MO) for
1 hr and dissociated into single cells in the presence of ROCK inhibitor before transduced with LP-
ZFN(CCR5), LP-ZFN(AAVS1), IDLV-ZFN(AAVS1)/puro and IDLV-ZFN(CCR5)/puro at a dose of 500 ng
p24 per 0.5105 cells. Five days after transduction, iPSCs treated with IDLV-ZFN(AAVS1)/puro and
IDLV-ZFN(CCR5)/puro were selected with puromycin (0.5 mg/ml). Representative clones were further
stained using alkaline phosphatase and TRA-1-60 live stain dyes (Life Technologies). For colony-form-
ing unit assays, after transduction with and incubation for 4 days, 1200 CD34+ cells were mixed with
Human Methylcellulose Complete Media (R&D Systems Inc., Minneapolis, MN) and transferred to a
35-mm plate. The plates were incubated in a humidified atmosphere with 5% (vol/vol) CO2 at 37˚C
for two weeks.
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Flow cytometry
HEK293T cells were seeded in 6-well plates (1105 cells/well) one day before transduction with 500
ng p24 IDLV-ZFN(AAVS1)/egfp or IDLV/egfp. Cells were fixed with 4% paraformaldehyde. Data
were collected on a FACSCalibur (BD Biosciences, Franklin Lakes, NJ). CD34+ Cells were analyzed
on LSRFortessa cell analyzer (BD Biosciences) for viability using the LIVE/DEAD fixable near-IR dead
cell stain kit (Life Technologies) 4 and 9 days after transduction and for the presence of eGFP+ cells
9 days after transduction.
Luciferase assay
HEK293T cells were seeded in 6-well plates (1105 cells/well) one day before transduction with 500
ng p24 IDLV-ZFN(AAVS1)/fluc or IDLV/fluc. Luminescence analysis was carried out 3, 10 and 18 days
after transduction, respectively. 0.5105 cells were transferred to 96-well plates 6 hr before lucifer-
ase activity analysis using ONE-Glo luciferase assay system (Promega, Madison, WI). Luminescence
analysis was performed on a multi-sample plate-reading luminometer (Berthold Technologies, Bad
Wildbad, Germany).
Surveyor nuclease assay
Surveyor nuclease assay (Integrated DNA Technologies, Leuven, Belgium) was used to determine
the frequencies of gene disruption as described previously (Cai et al., 2014a). Briefly, iPSCs or
CD34+ cells were incubated with ZFN-loaded LPs for 48 hr and collected for DNA extraction.
HEK293T cells transduced by IDLV-ZFN(AAVS1)/egfp or IDLV-ZFN(AAVS1)/fluc were also subjected
to Surveyor nuclease assay. CCR5 and AAVS1 fragments were amplified using primer sets YJ224F-
YJ225R and YJ222F-YJ223R, respectively. The PCR products were incubated with 1 ml Surveyor
nuclease plus 1 ml enhancer at 42˚C for 1 hr after denaturation and re-annealing. The cleavage prod-
ucts were separated on a 1.5% agarose gel and stained with ethidium bromide. The percentage of
indels was determined by the formula 100  (1 (1 fraction cleaved)1/2), wherein the fraction
cleaved is the sum of the cleavage product peaks divided by the sum of the cleavage product and
parent peaks.
Southern blot analysis
HEK293T cells were transduced with IDLV-ZFN(AAVS1)/puro or IDLV/puro at a dose of 500 ng p24
per 105 cells and selected by puromycin. The puromycin-resistant clones were isolated and
expanded for Southern blot analysis. Fifteen micrograms of genomic DNA from each clone was
digested overnight with BstXI or EcoNI (for subsequent hybridization with a puromycin and an
AAVS1 probe, respectively) before gel electrophoresis and vacuum blotting. The puromycin frag-
ment was derived from pLV/AAVS1-donor-puro-PGK using BstXI and SalI, whereas the AAVS1 probe
was amplified from genomic DNA by nested PCR using primer sets YJ599F-YJ600R and YJ601F-
YJ602R, successively. The iPSC clones derived from treatment with IDLV-ZFN(AAVS1)/puro were
prepared and analyzed in the same way, except for the use of a puromycin probe amplified from
pLV/AAVS1-donor-puro-PGK using primers Puro-1 and Puro-2. The probes were randomly labeled
using the Prime-It random primer labeling kit (Agilent Technologies, Santa Clara, CA) according to
the manufacturer’s instructions.
PCR analyses of targeted gene integration
Nested PCR reactions were performed to confirm homology-directed integration at the AAVS1 and
CCR5 loci. In the case of the AAVS1 locus, primer sets YJ706F-0279 and YJ707F-YJ738R were used
as first round and second round PCRs, respectively, to detect 5’ junctions. YJ251F-YJ205R and
YJ252F-YJ666R primer sets were used as first round and second round primer set, respectively, to
detect 3’ junctions. For insertion into the CCR5 locus, YJ825F-0279 and YJ833F-YJ738R were used
for amplification of 5’ junctions. Primer sets YJ251F-YJ253R and YJ252F-YJ208R were used to detect
3’ junctions. The CCR5 locus was amplified using primer set YJ224F-YJ225R, whereas the AAVS1
locus was amplified using primer set YJ222F-YJ223R.
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Karyotyping
For karyotyping analysis, actively growing cells on 6-well plate were treated with KaryoMAX Colce-
midSolution (0.1 mg/ml, ThermoFisher Scientific) for 2 hr at 37˚C. Cells were then swollen with warm
0.56% KCL for 10–15 min at 37˚C. After centrifugation, the cell pellets were fixed with fresh cold fix-
ative solution (methanol: acetic acid, 3:1) for 30 min on ice. Cells were gently washed twice with fixa-
tive solution. A drop of fixed cell suspension was dropped on a slide and then dried in a humid
condition. Metaphase chromosomes were imaged by microscope and analyzed by Quips CGH
software.
Next generation sequencing
The on-target and top ranking off-target loci of AAVS1 and CCR5 predicted by PROGNOS were
amplified from genomic DNA of iPSCs treated with IDLV-ZFN(AAVS1)/puro and IDLV-ZFN(CCR5)/
puro as well as from non-treated iPSCs using Phusion High-Fidelity PCR Master Mix (ThermoFisher
Scientific). Primers and predicted off-target loci are listed in Supplementary file 2B. The purified
PCR fragments amplified from each locus were mixed in equimolar amounts. Adaptors were ligated
to the pools, which were then deep sequenced with an Illumina HiSeq2500, HiSeq Rapid Run 125 bp
PE mode (GATC Biotech, Constance, Germany). The indel frequencies were analyzed using CRISP-
Resso (Pinello, 2015) using the CRISPRessoPooled amplicons mode, while ignoring substitutions.
Alternatively, and for further validation, the HiSeq reads were trimmed with Sickle (Joshi and Fass,
2011), merged with FLASH (Magocˇ and Salzberg, 2011), and mapped to the amplicons using bow-
tie2 (Langmead and Salzberg, 2012). Reads with an average Phred score below 23 were discarded.
The reads were then aligned using EMBOSS water (Rice, 2000) and analyzed for indels. The maxi-
mum-likelihood estimate of the true-indel fraction was calculated as previously described (Hsu et al.,
2013).
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